{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:33:55Z","timestamp":1777491235598,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migraine preventive medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an exploratory analysis of a randomized, double-blind, placebo-controlled, phase 3b trial for patients with chronic migraine or episodic migraine and inadequate response to 2 to 4 prior migraine preventive medication classes randomized (1:1:1) to fremanezumab (quarterly or monthly) or placebo. In this exploratory analysis, changes from baseline in the monthly average number of migraine days during 12 weeks of double-blind treatment and adverse events were evaluated for predefined subgroups of patients by number of prior preventive medication classes with inadequate response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 414, 265, and 153 patients had inadequate response to 2, 3, and 4 preventive medication classes, respectively. Changes from baseline in monthly average migraine days during 12 weeks were significantly greater with fremanezumab compared with placebo for patients with documented inadequate response to 2 classes (least-squares mean difference vs placebo [95% confidence interval]: quarterly, \u20132.9 [\u20133.83, \u20131.98]; monthly, \u20133.7 [\u20134.63, \u20132.75]), 3 classes (quarterly, \u20133.3 [\u20134.65, \u20131.95]; monthly, \u20133.0 [\u20134.25, \u20131.66]), and 4 classes (quarterly, \u20135.3 [\u20137.38, \u20133.22]; monthly, \u20135.4 [\u20137.35, \u20133.48]) of migraine preventive medications (all p\u2009&lt;\u20090.001). No significant treatment-by-subgroup interactions were observed for any outcome ( p interaction &gt; 0.20 for all). Adverse events were comparable for placebo and fremanezumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Significant improvements in efficacy were observed with fremanezumab compared with placebo, even in patients who had previously experienced inadequate response to 4 different classes of migraine preventive medications. ClinicalTrials.gov identifier: NCT03308968.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024211008401","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T22:05:56Z","timestamp":1621029956000},"page":"1075-1088","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0053-7003","authenticated-orcid":false,"given":"Ladislav","family":"Pazdera","sequence":"first","affiliation":[{"name":"Vestra Clinics, Rychnov nad Kn\u011b\u017enou, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M","family":"Cohen","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Ning","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena Ramirez","family":"Campos","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghua","family":"Yang","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR), Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"bibr1-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"bibr2-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1111\/head.13302"},{"key":"bibr3-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"bibr4-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-009-0048-3"},{"key":"bibr5-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1111\/head.12755"},{"key":"bibr6-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0946-z"},{"key":"bibr7-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"bibr8-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr9-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418788347"},{"key":"bibr10-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419835459"},{"key":"bibr11-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.3.283"},{"key":"bibr12-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"bibr13-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"bibr14-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"bibr15-03331024211008401","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211008401","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024211008401","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211008401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:03Z","timestamp":1777387743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024211008401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1177\/03331024211008401"],"URL":"https:\/\/doi.org\/10.1177\/03331024211008401","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]}}}